HC Wainwright Has Positive Forecast for KALV Q2 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Research analysts at HC Wainwright boosted their Q2 2026 earnings estimates for KalVista Pharmaceuticals in a research report issued to clients and investors on Thursday, March 12th. HC Wainwright analyst A. Fein now anticipates that the specialty pharmaceutical company will post earnings per share of ($0.42) for the quarter, up from their prior forecast of ($0.46). HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($1.23) EPS, FY2028 earnings at $2.25 EPS, FY2029 earnings at $3.56 EPS and FY2030 earnings at $3.83 EPS.

Several other analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Needham & Company LLC upped their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $16.82 on Monday. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The stock has a market cap of $850.25 million, a PE ratio of -4.26 and a beta of -0.35. KalVista Pharmaceuticals has a 12-month low of $9.23 and a 12-month high of $19.00. The business has a 50-day simple moving average of $15.78 and a two-hundred day simple moving average of $14.30.

Insiders Place Their Bets

In related news, insider Nicole Sweeny sold 3,975 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $61,890.75. Following the transaction, the insider directly owned 47,003 shares of the company’s stock, valued at $731,836.71. This represents a 7.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,693 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $16.08, for a total transaction of $107,623.44. Following the transaction, the chief executive officer owned 451,815 shares in the company, valued at approximately $7,265,185.20. The trade was a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 33,378 shares of company stock worth $522,290. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in KalVista Pharmaceuticals by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after acquiring an additional 88,720 shares during the period. Tudor Investment Corp ET AL bought a new position in KalVista Pharmaceuticals during the third quarter worth about $24,360,000. State Street Corp boosted its position in KalVista Pharmaceuticals by 21.3% during the fourth quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after purchasing an additional 336,195 shares during the period. Vestal Point Capital LP increased its stake in shares of KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after purchasing an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC increased its stake in shares of KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after purchasing an additional 1,055,940 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.